Short-course Rifamycin-based Regimens for Latent Tuberculosis in Patients With End-stage Kidney Disease

NCT05021731 · clinicaltrials.gov ↗

PHASE4

Phase

UNKNOWN

Status

225

Enrollment

OTHER

Sponsor class

Conditions

Latent Tuberculosis
Kidney Failure

Interventions

DRUG: Rifampicin plus Isoniazid
DRUG: Rifapentine plus Isoniazid
DRUG: Rifampicin alone

Sponsor

Miguel Santín

Collaborators

[object Object]
[object Object]